-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 20, the Liaoning Provincial Centralized Procurement Network for Drugs and Medical Consumables issued an announcement
for public comment on the "Fourth Batch of Interprovincial Alliance Drug Centralized Procurement Documents (Draft for Solicitation of Comments)" in the "Eight Provinces and Two Regions".
for public comment on the "Fourth Batch of Interprovincial Alliance Drug Centralized Procurement Documents (Draft for Solicitation of Comments)" in the "Eight Provinces and Two Regions".
The "Draft Opinions" clarifies that this collection and procurement will be carried out by comprehensive evaluation method, and the highest score will be selected by the selected enterprise, and the maximum number of selected enterprises
in the same variety of drugs will be produced.
in the same variety of drugs will be produced.
In addition, the non-selected drugs that fall within the scope of this procurement catalogue and the drugs that are not included in the same generic name and administration route of this collection are all included in the monitoring and management, and their procurement volume shall not exceed the agreed purchase quantity of
the selected drugs in principle.
the selected drugs in principle.
Previously, on June 7, Liaoning Province issued the "Announcement on Carrying out the Fourth Batch of Interprovincial Alliance Drug Centralized Procurement Work in the "Eight Provinces and Two Regions"", which showed that the alliance collection involved a total of 18 varieties
.
.
From the perspective of included varieties, 11 varieties of shiitake polysaccharide, compound vitamin (3), cefoperazone sodium tazobactam, sodium tetrahexose ganglioside monosialate, thymideptide, acetyl cysteine, sodium creatine phosphate, alprostadil, cefmetamexoxime hydrochloride, cefmondosteryl sodium, ceftezolium sodium ceftazole, etc.
are non-medical insurance varieties, in addition to a number of key monitoring varieties
such as tetrahexose monosialic acid ganglioside sodium, thymus pentagonin, sodium creatine phosphate, alprostadil and so on.
are non-medical insurance varieties, in addition to a number of key monitoring varieties
such as tetrahexose monosialic acid ganglioside sodium, thymus pentagonin, sodium creatine phosphate, alprostadil and so on.
In the alliance collection, the emergence of so many non-medical insurance and key monitored
varieties is still very rare.
varieties is still very rare.
The provinces participating in the alliance collection include 13 provinces (regions) such as Liaoning Province, Shanxi Province, Inner Mongolia Autonomous Region, Jilin Province, Heilongjiang Province, Hainan Province, Sichuan Province, Guizhou Province, Tibet Autonomous Region, Qinghai Province, Ningxia Autonomous Region, Xinjiang Autonomous Region, and Xinjiang Production and Construction Corps
.
.
The scope of medical institutions involved includes public medical institutions and military medical institutions in the provinces of the Alliance
.
Other medical insurance designated medical institutions shall be carried out
in accordance with the relevant regulations of each alliance region.
.
Other medical insurance designated medical institutions shall be carried out
in accordance with the relevant regulations of each alliance region.
At present, eight provinces and two districts have completed three batches of procurement
with volume.
The first batch was led by Sichuan, and the participating provinces were Liaoning, Jilin, Heilongjiang, Sichuan, Hainan, Shanxi, Tibet Autonomous Region and Inner Mongolia Autonomous Region, with 17 varieties procured and 15 final 11 varieties selected
from the specifications.
Compared with the 15 product regulations and the highest limited declared price of the winning bid, the average decrease was 58.
05%, and the highest decrease was 91.
69%.
Compared with the selected varieties and the existing hanging net prices in Sichuan Province, the average decrease was 77.
00%, and the highest decline was 98.
23%.
with volume.
The first batch was led by Sichuan, and the participating provinces were Liaoning, Jilin, Heilongjiang, Sichuan, Hainan, Shanxi, Tibet Autonomous Region and Inner Mongolia Autonomous Region, with 17 varieties procured and 15 final 11 varieties selected
from the specifications.
Compared with the 15 product regulations and the highest limited declared price of the winning bid, the average decrease was 58.
05%, and the highest decrease was 91.
69%.
Compared with the selected varieties and the existing hanging net prices in Sichuan Province, the average decrease was 77.
00%, and the highest decline was 98.
23%.
The second batch was led by Heilongjiang, and Qinghai and Guizhou were added to the first batch of provinces participating in the procurement of quantity, forming "eight provinces and two regions", 21 varieties entered the collection, a total of 145 pharmaceutical companies participated, and finally 14 pharmaceutical companies selected 16 product specifications, of which the highest price reduction was 92.
61%, and the average price reduction was 66.
71%.
61%, and the average price reduction was 66.
71%.
The third batch was led by Inner Mongolia and included 18 varieties, involving cardiovascular and cerebrovascular diseases, respiratory diseases and antibiotics and other common diseases and chronic diseases with large clinical
amounts.
In the end, 23 of the 17 varieties of 25 enterprises were selected to be selected, and the dihydroxyprophylline injection was streamed, with an average decrease of 54.
76%.
According to the People's Daily, among them, Dandong Medical Innovation Pharmaceutical's Piracetam injection dropped the most, with a drop of 98.
02%, and each stick dropped from 49.
6 yuan to 0.
98 yuan
.
amounts.
In the end, 23 of the 17 varieties of 25 enterprises were selected to be selected, and the dihydroxyprophylline injection was streamed, with an average decrease of 54.
76%.
According to the People's Daily, among them, Dandong Medical Innovation Pharmaceutical's Piracetam injection dropped the most, with a drop of 98.
02%, and each stick dropped from 49.
6 yuan to 0.
98 yuan
.
This is the fourth batch, which will be led by Liaoning, and the procurement rules are roughly the same as
the third batch.
the third batch.
Agreed purchase volume
The calculation base of the agreed purchase volume in the first year shall be determined
by each Union Province.
In principle, it is 70%
of the calculation base of the agreed purchase volume in the first year.
Among them, cefoperazone sodium tazobactam sodium, cefmetaxime hydrochloride, cefmondoster sodium, cefotizole sodium are 60% of the calculation base of the agreed purchase volume in the first year; Alprostadil, sodium creatine phosphate, thymus pentapeptide, etc.
are 50%
of the calculation base of the first year's agreed procurement.
by each Union Province.
In principle, it is 70%
of the calculation base of the agreed purchase volume in the first year.
Among them, cefoperazone sodium tazobactam sodium, cefmetaxime hydrochloride, cefmondoster sodium, cefotizole sodium are 60% of the calculation base of the agreed purchase volume in the first year; Alprostadil, sodium creatine phosphate, thymus pentapeptide, etc.
are 50%
of the calculation base of the first year's agreed procurement.
The principle of decomposition of purchase volumes
Each province of the alliance shall decompose the agreed procurement volume of the province according to the data (base) and proportion of the reported volume of
medical institutions.
medical institutions.
Procurement cycle
In principle, the procurement cycle of this centralized drug with quantity is 1 year, which can be extended by 1 year
according to the situation.
During the procurement cycle, the purchase agreement is signed
once a year.
When renewing the purchase agreement, the agreed procurement amount shall in principle not be less than the agreed purchase volume
of the selected drugs in each alliance province in the previous year.
During the procurement cycle, the selected enterprises that exceed the agreed purchase volume will still supply at the selected price until the expiration
of the procurement cycle.
according to the situation.
During the procurement cycle, the purchase agreement is signed
once a year.
When renewing the purchase agreement, the agreed procurement amount shall in principle not be less than the agreed purchase volume
of the selected drugs in each alliance province in the previous year.
During the procurement cycle, the selected enterprises that exceed the agreed purchase volume will still supply at the selected price until the expiration
of the procurement cycle.
During the procurement cycle, when the centralized procurement of the quantity overlaps with the selected drugs in the national collection, the provinces terminate the results of the centralized selection of the drugs when implementing the results of the selection of drugs organized by the state, and the agreed procurement amount is converted
according to the execution time.
If the selected drug encounters national policy adjustment or force majeure in the performance of the agreement, resulting in a direct impact on the performance of the agreement, it shall be resolved
through consultation between the two parties that signed the purchase and sale agreement.
according to the execution time.
If the selected drug encounters national policy adjustment or force majeure in the performance of the agreement, resulting in a direct impact on the performance of the agreement, it shall be resolved
through consultation between the two parties that signed the purchase and sale agreement.
Quotation Requirements:
The declared price shall not be higher than the highest valid declared price
.
The declared price exceeding the highest valid declared price is considered an invalid quotation
.
.
The declared price exceeding the highest valid declared price is considered an invalid quotation
.
Among them, the volume injection is based on the price of the same specification glass bottle packaging, the plastic bottle packaging plus 1 yuan, and the soft bag (refers to the packaging that completes the infusion without air) plus 4 yuan
.
Glass bottles, plastic bottles and soft pouch packaging are different in the specific form and material of each package, and the price
is not different.
.
Glass bottles, plastic bottles and soft pouch packaging are different in the specific form and material of each package, and the price
is not different.
Selection Rules:
A maximum of 1 selected enterprise
will be produced in the same variety of drugs.
This centralized procurement adopts the comprehensive evaluation method to review the product economic evaluation indicators (calculated according to comparable prices) and technical evaluation indicators, with a total score of 100 points, and the highest comprehensive evaluation score is the selected enterprise
.
will be produced in the same variety of drugs.
This centralized procurement adopts the comprehensive evaluation method to review the product economic evaluation indicators (calculated according to comparable prices) and technical evaluation indicators, with a total score of 100 points, and the highest comprehensive evaluation score is the selected enterprise
.
(1) 2 or more enterprises applying for drugs of the same variety shall be sorted from high to low according to the comprehensive evaluation score, and the highest score shall be determined as the enterprise
to be selected.
If the comprehensive evaluation scores are the same, they are determined
sequentially according to the scores of economic evaluation indicators, the scores of self-produced APIs, and the assessment of untrustworthiness.
to be selected.
If the comprehensive evaluation scores are the same, they are determined
sequentially according to the scores of economic evaluation indicators, the scores of self-produced APIs, and the assessment of untrustworthiness.
(2) If the reporting enterprise is 1, the quotation reduction is not less than the average reduction of all the declared products, and it is determined to be the selected enterprise, otherwise it will be processed
according to the flow standard.
according to the flow standard.
(3) The decline in the quotation of the drug to be selected is calculated
on the basis of the highest effective declared price declared by the enterprise.
on the basis of the highest effective declared price declared by the enterprise.
The purchase volume of non-selected varieties shall not exceed the agreed purchase volume of the selected varieties
The non-selected drugs that belong to the scope of this procurement catalogue and the drugs that are not included in the same generic name and the same route of administration are all included in the monitoring and management, and their procurement volume shall not exceed the agreed purchase quantity of the selected drugs in principle, and the specific requirements shall be formulated
by the alliance provinces in combination with the actual situation.
by the alliance provinces in combination with the actual situation.
On September 20, the Liaoning Provincial Centralized Procurement Network for Drugs and Medical Consumables issued an announcement
for public comment on the "Fourth Batch of Interprovincial Alliance Drug Centralized Procurement Documents (Draft for Solicitation of Comments)" in the "Eight Provinces and Two Regions".
for public comment on the "Fourth Batch of Interprovincial Alliance Drug Centralized Procurement Documents (Draft for Solicitation of Comments)" in the "Eight Provinces and Two Regions".
The "Draft Opinions" clarifies that this collection and procurement will be carried out by comprehensive evaluation method, and the highest score will be selected by the selected enterprise, and the maximum number of selected enterprises
in the same variety of drugs will be produced.
in the same variety of drugs will be produced.
In addition, the non-selected drugs that fall within the scope of this procurement catalogue and the drugs that are not included in the same generic name and administration route of this collection are all included in the monitoring and management, and their procurement volume shall not exceed the agreed purchase quantity of
the selected drugs in principle.
the selected drugs in principle.
Previously, on June 7, Liaoning Province issued the "Announcement on Carrying out the Fourth Batch of Interprovincial Alliance Drug Centralized Procurement Work in the "Eight Provinces and Two Regions"", which showed that the alliance collection involved a total of 18 varieties
.
.
From the perspective of included varieties, 11 varieties of shiitake polysaccharide, compound vitamin (3), cefoperazone sodium tazobactam, sodium tetrahexose ganglioside monosialate, thymideptide, acetyl cysteine, sodium creatine phosphate, alprostadil, cefmetamexoxime hydrochloride, cefmondosteryl sodium, ceftezolium sodium ceftazole, etc.
are non-medical insurance varieties, in addition to a number of key monitoring varieties
such as tetrahexose monosialic acid ganglioside sodium, thymus pentagonin, sodium creatine phosphate, alprostadil and so on.
are non-medical insurance varieties, in addition to a number of key monitoring varieties
such as tetrahexose monosialic acid ganglioside sodium, thymus pentagonin, sodium creatine phosphate, alprostadil and so on.
In the alliance collection, the emergence of so many non-medical insurance and key monitored
varieties is still very rare.
varieties is still very rare.
The provinces participating in the alliance collection include 13 provinces (regions) such as Liaoning Province, Shanxi Province, Inner Mongolia Autonomous Region, Jilin Province, Heilongjiang Province, Hainan Province, Sichuan Province, Guizhou Province, Tibet Autonomous Region, Qinghai Province, Ningxia Autonomous Region, Xinjiang Autonomous Region, and Xinjiang Production and Construction Corps
.
.
The scope of medical institutions involved includes public medical institutions and military medical institutions in the provinces of the Alliance
.
Other medical insurance designated medical institutions shall be carried out
in accordance with the relevant regulations of each alliance region.
Medicine and medicine.
Other medical insurance designated medical institutions shall be carried out
in accordance with the relevant regulations of each alliance region.
At present, eight provinces and two districts have completed three batches of procurement
with volume.
The first batch was led by Sichuan, and the participating provinces were Liaoning, Jilin, Heilongjiang, Sichuan, Hainan, Shanxi, Tibet Autonomous Region and Inner Mongolia Autonomous Region, with 17 varieties procured and 15 final 11 varieties selected
from the specifications.
Compared with the 15 product regulations and the highest limited declared price of the winning bid, the average decrease was 58.
05%, and the highest decrease was 91.
69%.
Compared with the selected varieties and the existing hanging net prices in Sichuan Province, the average decrease was 77.
00%, and the highest decline was 98.
23%.
with volume.
The first batch was led by Sichuan, and the participating provinces were Liaoning, Jilin, Heilongjiang, Sichuan, Hainan, Shanxi, Tibet Autonomous Region and Inner Mongolia Autonomous Region, with 17 varieties procured and 15 final 11 varieties selected
from the specifications.
Compared with the 15 product regulations and the highest limited declared price of the winning bid, the average decrease was 58.
05%, and the highest decrease was 91.
69%.
Compared with the selected varieties and the existing hanging net prices in Sichuan Province, the average decrease was 77.
00%, and the highest decline was 98.
23%.
The second batch was led by Heilongjiang, and Qinghai and Guizhou were added to the first batch of provinces participating in the procurement of quantity, forming "eight provinces and two regions", 21 varieties entered the collection, a total of 145 pharmaceutical companies participated, and finally 14 pharmaceutical companies selected 16 product specifications, of which the highest price reduction was 92.
61%, and the average price reduction was 66.
71%.
Enterprise enterprise61%, and the average price reduction was 66.
71%.
The third batch was led by Inner Mongolia and included 18 varieties, involving cardiovascular and cerebrovascular diseases, respiratory diseases and antibiotics and other common diseases and chronic diseases with large clinical
amounts.
In the end, 23 of the 17 varieties of 25 enterprises were selected to be selected, and the dihydroxyprophylline injection was streamed, with an average decrease of 54.
76%.
According to the People's Daily, among them, Dandong Medical Innovation Pharmaceutical's Piracetam injection dropped the most, with a drop of 98.
02%, and each stick dropped from 49.
6 yuan to 0.
98 yuan
.
Disease medicines and medicinesamounts.
In the end, 23 of the 17 varieties of 25 enterprises were selected to be selected, and the dihydroxyprophylline injection was streamed, with an average decrease of 54.
76%.
According to the People's Daily, among them, Dandong Medical Innovation Pharmaceutical's Piracetam injection dropped the most, with a drop of 98.
02%, and each stick dropped from 49.
6 yuan to 0.
98 yuan
.
This is the fourth batch, which will be led by Liaoning, and the procurement rules are roughly the same as
the third batch.
Procurement procurementthe third batch.
Agreed purchase volume
Agreed purchase volume The calculation base of the agreed purchase volume in the first year shall be determined
by each Union Province.
In principle, it is 70%
of the calculation base of the agreed purchase volume in the first year.
Among them, cefoperazone sodium tazobactam sodium, cefmetaxime hydrochloride, cefmondoster sodium, cefotizole sodium are 60% of the calculation base of the agreed purchase volume in the first year; Alprostadil, sodium creatine phosphate, thymus pentapeptide, etc.
are 50%
of the calculation base of the first year's agreed procurement.
by each Union Province.
In principle, it is 70%
of the calculation base of the agreed purchase volume in the first year.
Among them, cefoperazone sodium tazobactam sodium, cefmetaxime hydrochloride, cefmondoster sodium, cefotizole sodium are 60% of the calculation base of the agreed purchase volume in the first year; Alprostadil, sodium creatine phosphate, thymus pentapeptide, etc.
are 50%
of the calculation base of the first year's agreed procurement.
The principle of decomposition of purchase volumes
The principle of decomposition of purchase volumes Each province of the alliance shall decompose the agreed procurement volume of the province according to the data (base) and proportion of the reported volume of
medical institutions.
medical institutions.
Procurement cycle
Procurement cycle In principle, the procurement cycle of this centralized drug with quantity is 1 year, which can be extended by 1 year
according to the situation.
During the procurement cycle, the purchase agreement is signed
once a year.
When renewing the purchase agreement, the agreed procurement amount shall in principle not be less than the agreed purchase volume
of the selected drugs in each alliance province in the previous year.
During the procurement cycle, the selected enterprises that exceed the agreed purchase volume will still supply at the selected price until the expiration
of the procurement cycle.
according to the situation.
During the procurement cycle, the purchase agreement is signed
once a year.
When renewing the purchase agreement, the agreed procurement amount shall in principle not be less than the agreed purchase volume
of the selected drugs in each alliance province in the previous year.
During the procurement cycle, the selected enterprises that exceed the agreed purchase volume will still supply at the selected price until the expiration
of the procurement cycle.
During the procurement cycle, when the centralized procurement of the quantity overlaps with the selected drugs in the national collection, the provinces terminate the results of the centralized selection of the drugs when implementing the results of the selection of drugs organized by the state, and the agreed procurement amount is converted
according to the execution time.
If the selected drug encounters national policy adjustment or force majeure in the performance of the agreement, resulting in a direct impact on the performance of the agreement, it shall be resolved
through consultation between the two parties that signed the purchase and sale agreement.
according to the execution time.
If the selected drug encounters national policy adjustment or force majeure in the performance of the agreement, resulting in a direct impact on the performance of the agreement, it shall be resolved
through consultation between the two parties that signed the purchase and sale agreement.
Quotation Requirements:
Quotation Requirements: The declared price shall not be higher than the highest valid declared price
.
The declared price exceeding the highest valid declared price is considered an invalid quotation
.
.
The declared price exceeding the highest valid declared price is considered an invalid quotation
.
Among them, the volume injection is based on the price of the same specification glass bottle packaging, the plastic bottle packaging plus 1 yuan, and the soft bag (refers to the packaging that completes the infusion without air) plus 4 yuan
.
Glass bottles, plastic bottles and soft pouch packaging are different in the specific form and material of each package, and the price
is not different.
.
Glass bottles, plastic bottles and soft pouch packaging are different in the specific form and material of each package, and the price
is not different.
Selection Rules:
Selection Rules: A maximum of 1 selected enterprise
will be produced in the same variety of drugs.
This centralized procurement adopts the comprehensive evaluation method to review the product economic evaluation indicators (calculated according to comparable prices) and technical evaluation indicators, with a total score of 100 points, and the highest comprehensive evaluation score is the selected enterprise
.
will be produced in the same variety of drugs.
This centralized procurement adopts the comprehensive evaluation method to review the product economic evaluation indicators (calculated according to comparable prices) and technical evaluation indicators, with a total score of 100 points, and the highest comprehensive evaluation score is the selected enterprise
.
(1) 2 or more enterprises applying for drugs of the same variety shall be sorted from high to low according to the comprehensive evaluation score, and the highest score shall be determined as the enterprise
to be selected.
If the comprehensive evaluation scores are the same, they are determined
sequentially according to the scores of economic evaluation indicators, the scores of self-produced APIs, and the assessment of untrustworthiness.
to be selected.
If the comprehensive evaluation scores are the same, they are determined
sequentially according to the scores of economic evaluation indicators, the scores of self-produced APIs, and the assessment of untrustworthiness.
(2) If the reporting enterprise is 1, the quotation reduction is not less than the average reduction of all the declared products, and it is determined to be the selected enterprise, otherwise it will be processed
according to the flow standard.
according to the flow standard.
(3) The decline in the quotation of the drug to be selected is calculated
on the basis of the highest effective declared price declared by the enterprise.
on the basis of the highest effective declared price declared by the enterprise.
The purchase volume of non-selected varieties shall not exceed the agreed purchase volume of the selected varieties
The purchase volume of non-selected varieties shall not exceed the agreed purchase volume of the selected varieties The non-selected drugs that belong to the scope of this procurement catalogue and the drugs that are not included in the same generic name and the same route of administration are all included in the monitoring and management, and their procurement volume shall not exceed the agreed purchase quantity of the selected drugs in principle, and the specific requirements shall be formulated
by the alliance provinces in combination with the actual situation.
by the alliance provinces in combination with the actual situation.
